(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
(Address of principal executive offices)
|
(Zip Code)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
||
|
||||
|
Item 7.01 |
Regulation FD Disclosure.
|
Item 9.01. |
Financial Statements and Exhibits.
|
(d)
|
Exhibits.
|
Exhibit
No.
|
Description
|
Press Release dated January 9, 2023.
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
QUANTUM-SI INCORPORATED
|
||
By:
|
/s/ Claudia Drayton
|
|
Name:
|
Claudia Drayton
|
|
Title:
|
Chief Financial Officer
|
|
Date: January 9, 2023
|
● |
Quantum-Si has begun commercial shipments of the Platinum protein sequencing system.
|
● |
The Company announced a partnership with Aviva Systems Biology, a leading provider of antibody, protein, and immunoassay reagent products, to co-develop sample preparation kits for
protein sequencing research workflows with Platinum.
|
● |
Quantum-Si announced a partnership and license agreement with Biovista, an AI-driven bioscience firm, to integrate Biovista’s database and visualization technology into Quantum-Si’s Cloud
analytics to advance proteomics research, biomarker discovery, and drug development applications.
|
● |
The Company reaffirms commitment to fiscal discipline and seeks to extend cash runway beyond the current guidance of 2024.
|
-8?20$3;8T.P6BP^
M0"X99K>]9!:G
"?<:BWO'V@1\)EDIOJ3L>N4!+BF3Y9'RDRAP%
M%TTRGJ /3Q0/'RDLR)'$+'I@HVPFXJLM13%G075)PJ8=B_*9.B&W7J?VDI/D
MJJ8ZYHWT^[L6"EK&QO:;&Y.Y%^"2$AMBM3>QF]N(PHVX'T1%$>OY*3D-,S]*
MLD$JVMO9DYT5N#4LW#0//Y95J5FVF E
M*/ Q39:I4=>]OK\'UJ-6=
M7OX-4$L#!!0 ( %!&*594D=:N'P< %]& 4 <7-I+3(P,C,P,3 Y
M7V1E9BYX;6S5G%UOVS84AN\'[#]XWK4L6UZV):A;>&DR!$MK(\G0;3G&^?3D
MOO\=;OZMUQ.O=:I*IS)1FV/QU!J969W-E'BA2UFF6N;BPN1-K4WINN)EF?:%
M?YE_GINT*519B]0J66.0QNERUA[F[/SM5.=*C$;](?[O/QP.'K8&>&:JE=6S
M>2V&1T14^,!J,'[?=[/;^6^V$Q)XG)5B*9I28W]G'GWI1_.L+5JUP][DQ-
M6?>FLM#YZEA\_4X7RHD?U5*^%A^/'_:]$BUS5[_!IB=,<306T]=)[;*J\QX^)ZQ(0;
MN.(0,1TS1#,(1]T*E2B4)JTJ]]5MZ$:\$Q%SN9N*5,+9HFR6SXC'-)NOZ(,Z
MCNJ.>XZL.251==N24@O/:9YU+)$ZG'2R$0@-@*JUR.NS&8N* UGY98@6.3C&
M,F4M5]9>/&4F:O+)A5" O&8 ZJS-P*6)3M)5O?X$XW Y: FG-#6S1?1$_C$(OJ
MHU6LOIO)/R=4JE'6+9KV4JUCJB9/2RA-LJ']EUL28A_+[#XA#A2C_.K&+M!3
MKD'07H"5=NI.MX8X&EU#NRY3"K+S0.Q#\L"U?!F 3N;SPOU?M5!Y+Q.V%VEM
M>S71EL73B!O:=
&ULS9U=;]LX%H;O
M!YC_P/7.Q2Y0Q[&-+I"@\2";)H-@TR1(,NCN%H-"EFE'&%GT4DKM_/LE)=$6
MR4-*B:@/8#!U>=[SDB*?0]I*K'[Z=;<.T0],XX!$9X/QT?$ X<@GBR!:G0U>
MXJ$7^T$P^'7V\T^?_C(<_H8C3+T$+]#\%?V3$F]!@\4*H_N'NV408C29'(W9
M?T'0?3G*?_?W(LQ8OU&\>DN#LX&STFR.1V-MMOMT79Z1.AJ
M-#D^'H_^_>7FT7_&:V\81''B13X>(*8_C=/&&^)[23KH0OIN3D-A,!WM^S(J
M^-^&0C;D3\1/S/WQ^NC=DG(ZX813BY\>8X9%VFZN$U^S"Y^Q=^!?$U:"1^-4UM@!5'MP3#YG:$
MH1S!*7 89]&J+Y*L@Q+
:W%ZOUTY;=U!&A S4.]DL>XZSS1_!(;R'